Active-ingredient Dossier

Saxagliptin

Active-ingredient Dossier for Saxagliptin (dipeptidyl peptidase-4 inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by…

Brand: KOMBIGLYZE XR
Brand: ONGLYZA
Brand: QTERN
Therapeutic area: Endocrinology

What is

Saxagliptin Saxagliptin is a dipeptidyl peptidase-4 inhibitor.

Australian brands containing

Saxagliptin — ONGLYZA — QTERN — KOMBIGLYZE XR

Therapeutic areas

Saxagliptin is registered in endocrinology, with three brands available in this therapeutic area.

Sponsor landscape

AstraZeneca markets saxagliptin in Australia.

PBS and regulatory activity

One brand containing saxagliptin is listed on the PBS, with the latest schedule date being 1 May 2026. The latest PBAC outcome was recorded on 1 November 2017, and the latest AusPAR was issued on 7 March 2011.